珠海市妇幼保健院重型β-地中海贫血患儿的治疗现状及不规范治疗原因

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the non-standard treatments of children with β-thalasemiamajor(β-TM)and its causes,so as to reduce the proportion of non-standard treatments and improve the survival status of children.Methods A total of 57 cases of β-TM children treated in Zhuhai Municipal Maternity and Child Healthcare Hospital from January to December in 2018 were selected as the subjects,and the blood transfusion,iron removal,iron overload and the causes of non-standard treatment were investigated.Results Among the 57 children with β-TM,there were 13 children(22.8%)with irregular blood transfusion and 17 children(34.0%)with non-normative iron removal.Among the 57 children with β-TM,the reasons for irregular blood transfusion were 10 cases(17.5%)of family financial difficulties,and 3 cases(5.3%)of parents′neglect.Among the 50 children who needed to use iron removing drugs,the causes of nonnormative iron removal were 11 cases(22.0%)of family financial difficulties,3 cases(6.0%)of side effects of drugs,and 3 cases(6.0%)of parents′neglect.There was no significant difference in serum ferritin(SF)between regular and irregular blood transfusion groups(P＞0.05).The SF level in non-normative iron-removing group was higher than that in normative iron-removing group,and the difference was statistically significant(P＜0.05).Conclusion The proportion of non-standard treatments of children withβ-TM is high,most of which are related to economic difficulties.Increasing the income of medical insurance forminors will help to reduce the proportion of non-standard treatments and improve the prognosis of children with β-TM.

Key words： &beta -thalasemiamajor Children Treatment Iron overload

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DUAN Li
	LI Tong
	WANG Feng

Cite this article:

DUAN Li,LI Tong,WANG Feng. Current status of treatment for children with β-thalassem ia major in Zhuhai Municipal Maternity and Child Healthcare Hospital and reasons for non-standard treatment[J]. 中国当代医药, 2020, 27(9): 159-162.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I9/159

[1]	Orkin SH.Recentadvances in globin research using genomewide association studies and gene editing[J].Ann N Y Acad Sci，2016，1368（1）：5-10.
[2]	Sankaran VG，Xu J，Orkin SH.Advances in the understanding of haemoglobin switching[J].Br JHaematol，2010，49（2）：181-194.
[3]	中华医学会儿科学分会血液学组.重型β地中海贫血的诊断和治疗指南[J].中华儿科杂志，2018，56（10）：724-729.
[4]	中华医学会血液学分会/中国医师协会血液科医师分会.铁过载诊断与治疗的中国专家共识[J].中华血液学杂志，2011，32（8）：572-574.
[5]	Cappellini MD，Cohen A，Poter J，et al.Guidelines for the management of transfusion-dependent thalassaemia[Z].2014：2897.
[6]	Angelucci E，Barosi G，Camaschella C，et al.Italian society of hematology practice guidelines for the management of iron overload in thalassemiamajor and related disorders[J].Haematologica，2008，93（5）：741-752.
[7]	Cappellini MD，Cohen A，Eleftheriou A，et al.Guidelines forthe clinical management of thalassaemia[M].2nd revised edition.Nicosia （CY）：Thalassaemia International Federation，2008.
[8]	王燕燕，李晓辉，徐西华.地中海贫血诊治进展与我国现状[J].中国实用儿科杂志，2013，28（6）：473-476.
[9]	方建培，许吕宏.规范儿童重型β地中海贫血的诊治[J].中华儿科杂志，2010，48（3）：166-169.
[10]	周楠，金姣，黄璟，等.地中海贫血患儿家庭负担状况及其影响因素分析[J].中国实用儿科杂志，2018，33（12）：1004-1008.
[11]	赵雪丽.桂西地区重型β地中海贫血儿童生长发育及铁过载状况的调查研究[D].南宁：广西医科大学，2015.
[12]	刘兴玲，吴月勤，李惠森，等.126例重型β地中海贫血患儿输血治疗状况的调查[J].护理学报，2013，21（23）：19-22.
[13]	Filosa A，Vitrano A，Rigano P，et al.Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemiamajor[J].Blood cells Mol Dis，2013，51（2）：85-88.
[14]	Haghpanah S，Zarei T，Zahedi Z，et al.Compliance and satisfaction with defer-asirox（ExjadeR）compared with deferoxamine in patients with transfusion-dependentbeta thalassemia[J].Hematology，2014，19（4）：187-191.
[15]	Pepe A，Meloni A，Rossi G，et al.Cardiac and hepatic iron and ejection fraction in thalassemia major：multicentre prospective comparison of combined deferiprone and defer oxamine therapy against deferiprone or deferoxamine monotherapy[J].JCardiovasc Magn Reson，2013，88（8）：652-656.
[16]	Kwiatkowski JL.Current recommendations for chelation for transfusion-dependent thalassemia[J].Ann N Y Acad Sci，2016，1368（1）：107-114.